Skip to main content
Premium Trial:

Request an Annual Quote

Integrated DNA Technologies, ChosenMed Technology to Develop Gene Panels for Chinese Cancer Project

NEW YORK – Integrated DNA Technologies and Chinese medical sequencing firm ChosenMed are jointly developing large pan-cancer gene panels as part of the Cancer Genome Atlas of China (CGAC) project, IDT said today.

Under the strategic collaboration, IDT, a unit of Danaher, will provide its next-generation sequencing enrichment products for cancer sequencing to Beijing-based ChosenMed and help to enhance the firm's R&D capabilities.

Financial details of the agreement were not disclosed.

"This strategic cooperation allows our two organizations to leverage expertise in a joint effort to address future clinical needs," IDT President Trey Martin said in a statement.

IDT said the CGAC project, which is led by a Chinese government department that provides national standards for the registration of medical devices, has identified a clinical need for a large pan-cancer panel to standardize cancer diagnoses for Chinese patients. The two companies "will work together to build and develop future standards for NGS-based cancer diagnosis and, ultimately, treatment in China," according to IDT.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.